The group of sodium-glucose cotransporter-2 (SGLT2) inhibitors are promising hypoglycemic agents that have the added advantage of not promoting hyperinsulinemia, weight gain, or hypoglycemia, unlike traditional antidiabetic agents [165]. Here, SLC5A2 is linked to Hyperinsulinemia.